Archive

Older adults with HIV will nearly double by 2040. South Africa faces one of the sharpest rises, straining health systems.

Rosebank Health Village, a R100 million Growthpoint and Epione development, brings specialists, diagnostics and day surgery together.

Global HIV funding cuts pushed financing to a 20-year low in 2025, threatening prevention, research and the goal of ending AIDS by 2030.

Aspen HIV prevention pill licensing deal positions the SA manufacturer to supply lower-cost monthly PrEP across key African markets.

The Dis-Chem leadership succession ends as co-founder Ivan Saltzman leaves the board after 48 years, ending the family’s representation.

The Extensior launch in South Africa offers 15% lower semaglutide prices, but Discovery Health says scheme coverage is unlikely to expand.

Generic drug tariffs could raise US medicine costs, disrupt global supply chains and pressure manufacturers to move production to America.

Medicine safety is in focus as the iDexis court case raises questions about compounding, regulation and patient monitoring.

PEPFAR cuts have been linked to a 45% decline in South African children receiving HIV treatment at US-supported healthcare sites.

Fake medical certificates are driving sick leave abuse in South Africa, costing employers through absenteeism, fraud and lost productivity.

Aspen Semaglutide Canada gains Health Canada approval, but API supply problems could delay the generic’s commercial launch.